BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19537393)

  • 1. Is cytotoxic chemotherapy for lymphoma currently feasible for patients in Malawi? A debate.
    Crutchlow E; Miombe Y; Latham T
    Malawi Med J; 2008 Dec; 20(4):120-3. PubMed ID: 19537393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of the treatment of HIV-associated lymphoma.
    Kaplan LD
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):28-9. PubMed ID: 16163156
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
    Ratner L; Lee J; Tang S; Redden D; Hamzeh F; Herndier B; Scadden D; Kaplan L; Ambinder R; Levine A; Harrington W; Grochow L; Flexner C; Tan B; Straus D;
    J Clin Oncol; 2001 Apr; 19(8):2171-8. PubMed ID: 11304769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burkitt's lymphoma shortly after an acute HIV infection, treated with highly active retroviral treatment.
    Colebunders R; Dohmen S; Van de Velde A; Pelgrom J; Hermans P
    Acta Clin Belg; 2001; 56(5):321-2. PubMed ID: 11770227
    [No Abstract]   [Full Text] [Related]  

  • 5. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
    Navarro JT; Lloveras N; Ribera JM; Oriol A; Mate JL; Feliu E
    Haematologica; 2005 May; 90(5):704-6. PubMed ID: 15921395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-cancer agents. Unique protocol looks promising for lymphoma.
    TreatmentUpdate; 2003; 15(4):5-7. PubMed ID: 17216853
    [No Abstract]   [Full Text] [Related]  

  • 7. HIV-related lymphoma treated with maintenance thalidomide.
    Larson ML; Enschede SH; Gregory SA
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):231-4; discussion 234-5. PubMed ID: 16166993
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
    Toffoli G; Corona G; Cattarossi G; Boiocchi M; Di Gennaro G; Tirelli U; Vaccher E
    Ann Oncol; 2004 Dec; 15(12):1805-9. PubMed ID: 15550586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection.
    Spina M; Gabarre J; Fasan M; Vaccher E; Tirelli U
    AIDS; 2000 Jul; 14(10):1457-8. PubMed ID: 10930165
    [No Abstract]   [Full Text] [Related]  

  • 10. AIDS-related non-Hodgkin lymphoma: still a problem in the era of HAART.
    Aboulafia DM; Pantanowitz L; Dezube BJ
    AIDS Read; 2004 Nov; 14(11):605-17. PubMed ID: 15570672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.
    Levine AM; Noy A; Lee JY; Tam W; Ramos JC; Henry DH; Parekh S; Reid EG; Mitsuyasu R; Cooley T; Dezube BJ; Ratner L; Cesarman E; Tulpule A
    J Clin Oncol; 2013 Jan; 31(1):58-64. PubMed ID: 23169503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
    Levine AM; Tulpule A; Espina B; Sherrod A; Boswell WD; Lieberman RD; Nathwani BN; Welles L
    J Clin Oncol; 2004 Jul; 22(13):2662-70. PubMed ID: 15226333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
    Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
    Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC; Best JH
    Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG).
    Hentrich M; Hoffmann C; Mosthaf F; Müller M; Siehl J; Wyen C; Hensel M; ;
    Ann Hematol; 2014 Jun; 93(6):913-21. PubMed ID: 24807241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
    J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F; Ravasio R
    Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
    Little RF; Pittaluga S; Grant N; Steinberg SM; Kavlick MF; Mitsuya H; Franchini G; Gutierrez M; Raffeld M; Jaffe ES; Shearer G; Yarchoan R; Wilson WH
    Blood; 2003 Jun; 101(12):4653-9. PubMed ID: 12609827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
    Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E
    Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.